p.6 抽出テキスト

............................................................................................................................................................................ AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management (trial) AFFIRM-AHF A Randomized, Double-blind Placebocontrolled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalizations and Mortality in Irondeficient Subjects Admitted for Acute Heart Failure (trial) AHF Acute heart failure AL Light chain immunoglobulin AL-CA Light chain immunoglobulin cardiac amyloidosis AMICA Atrial Fibrillation Management in Congestive Heart Failure With Ablation (trial) ANCA Antineutrophil cytoplasmic antibody ARB Angiotensin-receptor blocker ARNI Angiotensin receptor-neprilysin inhibitor ARVC Arrhythmogenic right ventricular cardiomyopathy ATTR Transthyretin amyloidosis AV Atrio-ventricular b.i.d. Bis in die (twice daily) BAG3 Bcl2-associated athanogene 3 BiVAD Biventricular assist device BMI Body mass index BNP B-type natriuretic peptide BP Blood pressure b.p.m. Beats per minute BTB Bridge to bridge BTC Bridge to candidacy BTD Bridge to decision BTR Bridge to recovery BTT Bridge to transplantation CA Cardiac amyloidosis (or amyloid cardiomyopathy) CABANA Catheter ABlation vs. ANti-arrhythmic drug therapy for Atrial fibrillation (trial) CABG Coronary artery bypass graft CAD Coronary artery disease CANVAS-R CANagliflozin cardioVascular Assessment Study - Renal CARE-HF CArdiac REsynchronization in Heart Failure CASTLE-AF Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular and Atrial Fibrillation (trial) CCB Calcium channel blocker CCS Chronic coronary syndrome CHA2DS2-VASc Congestive heart failure or left ventricular dysfunction, Hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled)- Vascular disease, Age 6574, Sex category (female) (score) CHAMPIT Acute Coronary syndrome/Hypertension emergency/Arrhythmia/acute Mechanical cause/Pulmonary embolism/Infections/ Tamponade CHARM Candesartan in Heart Failure - Assessment of moRtality and Morbidity (trial) CHF Chronic heart failure CI Confidence interval CKD Chronic kidney disease CMP Cardiomyopathy CMR Cardiac magnetic resonance CMV Cytomegalovirus COAPT Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for HF patients with functional mitral regurgitation (trial) COC Cardio-Oncology Council (part of the European Society of Cardiology) COMMANDER-HF A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (trial) COMPASS Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (trial) COPD Chronic obstructive pulmonary disease CORONA COntrolled ROsuvastatin multiNAtional (trial) COVID-19 Coronavirus disease 2019 CR Controlled release CREDENCE Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (trial) CRT Cardiac resynchronization therapy CRT-D Cardiac resynchronization therapy with defibrillator CRT-P Cardiac resynchronization therapy pacemaker CSA Central sleep apnoea CT Computed tomography CTCA Computed tomography coronary angiography CV Cardiovascular DAPA-HF Dapagliflozin And Prevention of Adverseoutcomes in Heart Failure (trial) DCM Dilated cardiomyopathy DECLARE- TIMI 58

Dapagliflozin Effect on CardiovascuLAR Events (Thrombolysis in Myocardial Infarction) (trial) DIAMOND Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (trial) DIG Digitalis Investigation Group (trial) DNA Deoxyribonucleic acid DOAC Direct-acting oral anticoagulant DPD 3,3-diphosphono-1,2-propanodicarboxylic acid Downloaded from academic.oup.com/eurheartj/article/42/36/3599/6358045 by guest on 07 October 2026